CorMedix Inc.

**Signal Note: Deerfield initiates $12.9M position in CRMD** Deerfield's entry suggests conviction in CorMedix's core asset Neurochlor (chlorhexidine-based catheter lock), which addresses central-line-associated bloodstream infections (CLABSI) in hemodialysis patients—a high-volume, reimbursed indication with limited competition. The timing may reflect anticipation of upcoming label expansion data or commercial inflection following recent FDA clearances for additional patient populations.